Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech, Inc. is set to host an engaging Virtual Acute Myeloid Leukemia KOL event on October 14, 2024, which will feature discussions with top medical experts on the potential of Annamycin to revolutionize AML treatment. The company also highlights their pivotal Phase 3 MIRACLE trial aimed at accelerated approval of Annamycin in combination with cytarabine for patients with relapsed or refractory AML. Investors and interested parties can join the event via webcast to gain insights into Moleculin’s advanced pipeline targeting challenging tumors and viruses.
See more insights into MBRX stock on TipRanks’ Stock Analysis page.
